Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2051)	12/19/2007 2:37:05 PM
From: Jibacoa	Respond to of 3722

ABII Has continued its up-move <g> bigcharts.marketwatch.com Its nab technology platform is the first to maximize the tumor’s biology against itself, taking advantage of an albumin-specific, receptor-mediated transport system and allowing the delivery of a drug from the vascular space across the blood vessel wall to the underlying tumor tissue. On Nov 27 it announced that it has granted an exclusive license to Green Cross Corp for the commercialization of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) in Korea. And Green Cross has granted an exclusive license to ABII for the future commercialization of biosimilars in the U.S. & Canada of erythropoetin, pegylated G-CSF, Interferon-Alpha, recombinant Factor VIII, & etanercept. The FDA approved ABRAXANE in Jan 2005 for the treatment of breast Ca after failure of combination chemo for metastatic disease or relapse within 6 months of adjuvant chemotherapy. On Dec 3, ABII's subsidiary, Cenomed, announced that it has signed an agreement with ThioPharma to develop a drug delivery technology, which will be used with certain of Cenomed’s psychiatric and neurological disease programs. At any rate, ABII stock remains on a strong UT.<g> bigcharts.marketwatch.com Bernard